Amylin Pharmaceuticals, Inc. (AMLN)

carwasher1 (62.29) Submitted: 8/24/06 3:46 AM : Start Price: $44.74 AMLN Score: -37.81

This company has no where to go but up, albiet slowly. It has a diabetes drug that also helps loose weight. With diabetes and obesity on the rise world wide and Doctors just gaining info on their new drug, it would seem a true winner for all.

Report this Post Replies: 1 | Reply | Permalink

NetscribeBiotech (66.48) Submitted: 2/09/07 7:53 AM : Start Price: $41.58 AMLN Score: -21.02

Amylin Pharmaceuticals (AMLN) is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines for the treatment of diabetes, obesity and cardiovascular disease. With two approved product offerings include Byett...

Report this Post Replies: 0 | Reply | Permalink

stratton6 (44.22) Submitted: 8/06/06 5:03 PM : Start Price: $47.41 AMLN Score: -43.73

Demand for exenatide is exdeeding capacity (Partnered with Lilly). Collaboration with Alkermes for extended delivery of this product.

Report this Post Replies: 0 | Reply | Permalink

TotoMMB (90.57) Submitted: 12/24/07 4:09 AM : Start Price: $38.00 AMLN Score: -11.26

Real hit or miss buy. Seems to be stuck between 35 and 50. Currently on the low end, I'd buy, only to ride the roller coaster. With only a couple products to it's name, it's going to hit big or miss big. While that may be a ways off, it may pop back ...

Report this Post Replies: 0 | Reply | Permalink

PDTBiotech (25.59) Submitted: 3/25/08 11:45 AM : Start Price: $29.02 AMLN Score: 5.00

AMLN develops, manufactures, and sells drugs for the treatment of diabetes, obesity, and cardiovascular disease. I’ll dispense with the obligatory “gee-whiz” numbers here, but needless to say whoever can gain a foothold in this field and maintain it...

Report this Post Replies: 0 | Reply | Permalink

faroutpicks (< 20) Submitted: 10/18/07 10:18 PM : Start Price: $45.62 AMLN Score: -22.71

Not sure when the FDA will approve their drug for diabeties, but if it only takes one hit per week my baby boomer bros will be relieved. I don't have type 1 or type 2, but if I sit too long rating stocks and don't exercise I will be headed in that d...

Report this Post Replies: 0 | Reply | Permalink

MLErik (47.47) Submitted: 12/01/07 3:07 AM : Start Price: $37.88 AMLN Score: -11.40

Nearing support at $36, the data from the last drug trials was positive. The diabetes market is huge and Amlyin is extremely attractive to the bigger names that have no growth left (PFE)

Report this Post Replies: 0 | Reply | Permalink

rangercapt (47.41) Submitted: 12/11/06 7:58 PM : Start Price: $38.58 AMLN Score: -17.35

AMLN is more then just a diabetes treatment. It is going to evetually provide enough information to prevent it from getting worse and may reverse this deadly disease. Other companies are trying to make inhalable insulin when they should be trying t...

Report this Post Replies: 0 | Reply | Permalink

donklenzman (83.40) Submitted: 9/14/06 10:25 AM : Start Price: $46.08 AMLN Score: -38.34

20+million diabetics

Report this Post Replies: 0 | Reply | Permalink

genedom (97.00) Submitted: 1/30/08 2:28 PM : Start Price: $29.11 AMLN Score: 6.84

AMLN is pricey at 50, but under 30, it is a bargain.
This is a solid biotech with two drugs in metabolic disease area and a strong pipeline. The revenue growth in the next two year will be slow, which is the reason it is out of market favor now. As t...

Report this Post Replies: 0 | Reply | Permalink